1.1Citrate controls solution ph
The ratio of citric acid to sodium citrate sets the pH of the aqueous formulation. The target pH comes from a stability study that measures the compound and its degradation products across a series of pH values.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The ratio of citric acid to sodium citrate sets the pH of the aqueous formulation. The target pH comes from a stability study that measures the compound and its degradation products across a series of pH values.
Trehalose dissolves in the aqueous fill and forms an amorphous matrix during freeze-drying. Secondary drying lowers residual moisture, and the matrix limits molecular mobility during storage.
A sterile crystalline powder is filled into vials under low-humidity conditions and sealed with a moisture-resistant closure. Sterile diluent is added immediately before use, which limits the time the compound spends in water.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
The formula (I) compound and arginine are dissolved together to prepare a reference material for training analytical laboratory staff. The material is divided into single-use aliquots, and trainees dilute each aliquot with the chromatographic sample diluent before injection. Trainees compare replicate peak areas and retention times to assess the repeatability of their sample preparation and instrument operation.
L-lysine replaces arginine in a formulation test solution containing the formula (I) compound or its pharmaceutically acceptable salt. The lysine solution receives the same molar amount of amino acid as a parallel arginine reference, and both solutions start at the same pH and active compound concentration. Liquid chromatography measures active compound content and degradation products in both preparations over the same storage interval.
The formula (I) compound and arginine are dissolved in a single bulk solution that is dispensed into identical glass vials at fill volumes of 1 mL and 4 mL. Each fill volume undergoes a separate freeze-drying run, with temperature probes positioned near the vial bottoms in center and edge locations. Residual moisture is measured after drying, and the drying hold for each fill volume is set from the measured moisture and temperature profiles.
A dual chamber cartridge holds the dried formula (I) compound and arginine in its front chamber and sterile water in its rear chamber. A movable stopper separates the chambers during storage, and a bypass channel is formed in the cartridge wall. Plunger travel moves the stopper into the bypass zone, where water flows into the front chamber and dissolves the dried contents.
Separate stock vessels hold solutions of the formula (I) compound and arginine, and metering pumps feed both stocks into a mixing vessel on a load cell. A controller calculates each addition mass from the assayed stock concentration expressed per unit mass and the target amount in the batch. The controller dispenses the stocks sequentially, records each settled mass increment, and flags additions outside the configured mass tolerances.
Sealed aliquots containing the formula (I) compound and arginine are stored in temperature-controlled chambers and assigned barcode identifiers linked to their storage conditions and sampling times. A liquid-handling robot scans each retrieved aliquot, dilutes it with sample diluent, and transfers it to a vial for liquid chromatography. Software links the resulting active compound and degradation-product measurements to the original aliquot and plots each measurement against elapsed storage time.
A sodium salt formed at an ionizable carboxyl group of the formula (I) compound supplies the antibacterial ingredient. L-arginine dissolves in the aqueous fill before the sodium salt is added, and the final pH is measured before filtration.
The formula (I) compound and crystalline L-arginine are metered as separate powder fractions into the same sterile vial. Both fractions dissolve when the specified volume of sterile diluent is added and the vial is gently swirled.
patent.fyi, US 2026/0355210 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355210/, SHA-256 3bae2c08fd65d54c22e7bcf867d68dc83ff1b904f864ef0bda6ebc613ec8b827